
On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law.
AMCP recognizes the importance of efforts to make prescription drugs more affordable for Medicare beneficiaries and urges CMS to continually and rigorously oversee the program’s implementation and its broader effects to ensure that it does not unintentionally hinder innovation and the development of new therapies. CMS should monitor the downstream impact of the Medicare Drug Price Negotiation Program on innovation and drug development and take appropriate action as needed to ensure that the United States remains the leader in pharmaceutical innovation.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.